Skip to main content
SpringerLink
Log in

Gordon Syndrome: a continuing story

  • Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Gordon Syndrome (GS) is a rare familial hypertension syndrome with a characteristic hyperkalaemia which distinguishes it from other syndromic forms of hypertension that typically cause hypokalaemia. Patients with GS respond to aggressive salt-restriction or relatively small doses of thiazide diuretics, which suggests that activation of the thiazide-sensitive Na/Cl cotransporter (NCC) in the distal nephron is to blame. However, the mechanism has proved to be complex. In 2001, mutations in genes encoding two serine/threonine kinases, WNK1 and WNK4, were identified as causing GS. However, it took several years to appreciate that these kinases operated in a cascade with downstream serine/threonine kinases (SPAK and OSR1) actually phosphorylating and activating NCC and the closely related cotransporters NKCC1 and NKCC2. The hyperkalaemia in GS arises from an independent action of WNK1/WNK4 to reduce cell-surface expression of ROMK, the secretory K-channel in the collecting ducts. However, mutations in WNK1/4 are present in a small minority of GS families, and further genes have emerged (CUL3 and KLHL3) that code for Cullin-3 (a scaffold protein in an ubiquitin–E3 ligase) and an adaptor protein, Kelch3, respectively. These new players regulate the ubiquitination and proteasomal degradation of WNK kinases, thereby adding to the complex picture we now have of NCC regulation in the distal nephron.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Paver W, Pauline G (1964) Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust 2:305–306

    CAS  PubMed  Google Scholar 

  2. Gordon RD, Geddes RA, Pawsey CG, O’Halloran MW (1970) Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 19:287–294

    CAS  PubMed  Google Scholar 

  3. Toka HR, Koshy JM, Hariri A (2013) The molecular basis of blood pressure variation. Pediatr Nephrol 28:387–399

    Article  PubMed  Google Scholar 

  4. Achard JM, Disse-Nicodeme S, Fiquet-Kempf B, Jeunemaitre X (2001) Phenotypic and genetic heterogeneity of familial hyperkalaemic hypertension (Gordon syndrome). Clin Exp Pharmacol Physiol 28:1048–1052

    Article  CAS  PubMed  Google Scholar 

  5. Mayan H, Vered I, Mouallem M, Tzadok-Witkon M, Pauzner R, Farfel Z (2002) Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrinol Metab 87:3248–3254

    Article  CAS  PubMed  Google Scholar 

  6. Gordon RD, Hodsman GP (1986) The syndrome of hypertension and hyperkalaemia without renal failure: long term correction by thiazide diuretic. Scott Med J 31:43–44

    CAS  PubMed  Google Scholar 

  7. Mansfield TA, Simon DB, Farfel Z, Bia M, Tucci JR, Lebel M, Gutkin M, Vialettes B, Christofilis MA, Kauppinen Makelin R, Mayan H, Risch N, Lifton RP (1997) Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31–42 and 17p11–q21. Nat Genet 16:202–205

    Article  CAS  PubMed  Google Scholar 

  8. O’Shaughnessy KM, Fu B, Johnson A, Gordon RD (1998) Linkage of Gordon’s syndrome to the long arm of chromosome 17 in a region recently linked to familial essential hypertension. J Hum Hypertens 12:675–678

    Article  PubMed  Google Scholar 

  9. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, Lifton RP (2001) Human hypertension caused by mutations in WNK kinases. Science 293:1107–1112

    Article  CAS  PubMed  Google Scholar 

  10. Verissimo F, Jordan P (2001) WNK kinases, a novel protein kinase subfamily in multi-cellular organisms. Oncogene 20:5562–5569

    Article  CAS  PubMed  Google Scholar 

  11. Uchida S, Sohara E, Rai T, Sasaki S (2014) Regulation of with-no-lysine kinase signaling by Kelch-like proteins. Biol Cell 106:45–56

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Ohta A, Schumacher FR, Mehellou Y, Johnson C, Knebel A, Macartney TJ, Wood NT, Alessi DR, Kurz T (2013) The CUL3-KLHL3 E3 ligase complex mutated in Gordon’s hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction. Biochem J 45:111–122

    Article  Google Scholar 

  13. Kahle KT, Gimenez I, Hassan H, Wilson FH, Wong RD, Forbush B, Aronson PS, Lifton RP (2004) WNK4 regulates apical and basolateral Cl- flux in extrarenal epithelia. Proc Natl Acad Sci USA 101:2064–2069

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Choate KA, Kahle KT, Wilson FH, Nelson-Williams C, Lifton RP (2003) WNK1, a kinase mutated in inherited hypertension with hyperkalemia, localizes to diverse Cl–transporting epithelia. Proc Natl Acad Sci USA 100:663–668

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Yang CL, Angell J, Mitchell R, Ellison DH (2003) WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 111:1039–1045

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP (2003) Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci USA 100:680–684

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Golbang AP, Murthy M, Hamad A, Liu CH, Cope G, Van’t Hoff W, Cuthbert A, O’Shaughnessy KM (2005) A new kindred with pseudohypoaldosteronism type II and a novel mutation (564D>H) in the acidic motif of the WNK4 gene. Hypertension 46:295–300

    Article  CAS  PubMed  Google Scholar 

  18. Zhou B, Zhuang J, Gu D, Wang H, Cebotaru L, Guggino WB, Cai H (2010) WNK4 enhances the degradation of NCC through a Sortilin-mediated lysosomal pathway. J Am Soc Nephrol 21:82–92

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Vitari AC, Deak M, Morrice N, Alessi DR (2005) The WNK1 and WNK4 protein kinases that are mutated in Gordon’s hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases. Biochem J 391:17–24

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Alessi DR, Zhang J, Khanna A, Hochdorfer T, Shang Y, Kahle KT (2014) The WNK-SPAK/OSR1 pathway: master regulator of cation-chloride cotransporters. Sci Signal 7:re3

    Article  PubMed  Google Scholar 

  21. Rosenbaek LL, Kortenoeven MLA, Aroankins TS, Fenton RA (2014) Phosphorylation decreases ubiquitylation of the Thiazide-sensitive cotransporter NCC and subsequent clathrin-mediated endocytosis. J Biol Chem 289:13347–13361

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Glover M, Mercier Zuber A, Figg N, O’Shaughnessy KM (2010) The activity of the thiazide-sensitive Na(+)-Cl(-) cotransporter is regulated by protein phosphatase PP4. Can J Physiol Pharmacol 88:986–995

    Article  CAS  PubMed  Google Scholar 

  23. Pacheco-Alvarez D, Cristobal PS, Meade P, Moreno E, Vazquez N, Munoz E, Diaz A, Juarez ME, Gimenez I, Gamba G (2006) The Na+:Cl- cotransporter is activated and phosphorylated at the amino-terminal domain upon intracellular chloride depletion. J Biol Chem 281:28755–28763

    Article  CAS  PubMed  Google Scholar 

  24. Yang S-S, Fang Y-W, Tseng M-H, Chu P-Y, Yu I-S, Wu H-C, Lin S-W, Chau T, Uchida S, Sasaki S, Lin Y-F, Sytwu H-K, Lin S-H (2013) Phosphorylation regulates NCC stability and transporter activity in vivo. J Am Soc Nephrol 24:1587–1597

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Chavez-Canales M, Zhang C, Soukaseum C, Moreno E, Pacheco-Alvarez D, Vidal-Petiot E, Castaneda-Bueno M, Vazquez N, Rojas-Vega L, Meermeier NP, Rogers S, Jeunemaitre X, Yang CL, Ellison DH, Gamba G, Hadchouel J (2014) WNK-SPAK-NCC cascade revisited: WNK1 stimulates the activity of the Na-Cl cotransporter via SPAK, an effect antagonized by WNK4. Hypertension. doi:10.1161/HYPERTENSIONAHA.114.04036

    PubMed  Google Scholar 

  26. Cope G, Golbang A, Murthy M, Hamad A, Liu CH, Hoff WV, Cuthbert A, O’Shaughnessy KM (2006) WNK1 affects surface expression of the ROMK potassium channel independent of WNK4. J Am Soc Nephrol 17:1867–1874

    Article  CAS  PubMed  Google Scholar 

  27. Kahle KT, Wilson FH, Leng Q, Lalioti MD, O’Connell AD, Dong K, Rapson AK, MacGregor GG, Giebisch G, Hebert SC, Lifton RP (2003) WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. Nat Genet 35:372–376

    Article  CAS  PubMed  Google Scholar 

  28. Lazrak A, Liu Z, Huang CL (2006) Antagonistic regulation of ROMK by long and kidney-specific WNK1 isoforms. Proc Natl Acad Sci USA 103:1615–1620

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Vidal-Petiot E, Elvira-Matelot E, Mutig K, Soukaseum C, Baudrie V, Wu S, Cheval L, Huc E, Cambillau M, Bachmann S, Doucet A, Jeunemaitre X, Hadchouel J (2013) WNK1-related familial hyperkalemic hypertension results from an increased expression of L-WNK1 specifically in the distal nephron. Proc Natl Acad Sci USA 110:14366–14371

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Valimaki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TR, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP (2012) Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 482:98–102

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Louis-Dit-Picard H, Barc J, Trujillano D, Miserey-Lenkei S, Bouatia-Naji N, Pylypenko O, Beaurain G, Bonnefond A, Sand O, Simian C, Vidal-Petiot E, Soukaseum C, Mandet C, Broux F, Chabre O, Delahousse M, Esnault V, Fiquet B, Houillier P, Bagnis CI, Koenig J, Konrad M, Landais P, Mourani C, Niaudet P, Probst V, Thauvin C, Unwin RJ, Soroka SD, Ehret G, Ossowski S, Caulfield M, Bruneval P, Estivill X, Froguel P, Hadchouel J, Schott JJ, Jeunemaitre X (2012) KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet 44:456–460

    Article  CAS  PubMed  Google Scholar 

  32. Glover M, Ware JS, Henry A, Wolley M, Walsh R, Wain LV, Xu S, Van’t Hoff WG, Tobin MD, Hall IP, Cook S, Gordon RD, Stowasser M, O’Shaughnessy KM (2014) Detection of mutations in KLHL3 and CUL3 in families with FHHt (familial hyperkalaemic hypertension or Gordon’s syndrome). Clin Sci (Lond) 126:721–726

    Article  CAS  Google Scholar 

  33. Susa K, Sohara E, Rai T, Zeniya M, Mori Y, Mori T, Chiga M, Nomura N, Nishida H, Takahashi D, Isobe K, Inoue Y, Takeishi K, Takeda N, Sasaki S, Uchida S (2014) Impaired degradation of WNK1 and WNK4 kinases causes PHAII in mutant KLHL3 knock-in mice. Hum Mol Genet. doi:10.1093/hmg/ddu217

    PubMed  Google Scholar 

  34. Disse-Nicodeme S, Desitter I, Fiquet-Kempf B, Houot AM, Stern N, Delahousse M, Potier J, Ader JL, Jeunemaitre X (2001) Genetic heterogeneity of familial hyperkalaemic hypertension. J Hypertens 19:1957–1964

    Article  CAS  PubMed  Google Scholar 

  35. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O’Rahilly S (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880–883

    CAS  PubMed  Google Scholar 

  36. Pelham CJ, Ketsawatsomkron P, Groh S, Grobe JL, de Lange WJ, Ibeawuchi SR, Keen HL, Weatherford ET, Faraci FM, Sigmund CD (2012) Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARgamma and RhoA/Rho-kinase. Cell Metab 16:462–472

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Wang Y, O’Connell JR, McArdle PF, Wade JB, Dorff SE, Shah SJ, Shi X, Pan L, Rampersaud E, Shen H, Kim JD, Subramanya AR, Steinle NI, Parsa A, Ober CC, Welling PA, Chakravarti A, Weder AB, Cooper RS, Mitchell BD, Shuldiner AR, Chang YP (2009) Whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci USA 106:226–231

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Alessi DR, Zhang J, Khanna A, Hochdörfer T, Shang Y, Kahle KT (2014) The WNK-SPAK/OSR1 pathway: master regulator of cation-chloride cotransporters. Sci Signal 7(334):re3

    Article  PubMed  Google Scholar 

  39. Siew K, O’Shaughnessy KM (2013) Extrarenal roles of the with-no-lysine[K] kinases (WNKs). Clin Exp Pharmacol Physiol 40:885–894

    Article  CAS  PubMed  Google Scholar 

  40. Mori T, Kikuchi E, Watanabe Y, Fujii S, Ishigami-Yuasa M, Kagechika H, Sohara E, Rai T, Sasaki S, Uchida S (2013) Chemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy. Biochem J 455:339–345

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, Addenbrooke’s Hospital–University of Cambridge, Cambridge, CB2 2QQ UK

    Kevin M. O’Shaughnessy

Authors
  1. Kevin M. O’Shaughnessy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin M. O’Shaughnessy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

O’Shaughnessy, K.M. Gordon Syndrome: a continuing story. Pediatr Nephrol 30, 1903–1908 (2015). https://doi.org/10.1007/s00467-014-2956-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-014-2956-7

Keywords

Search

Navigation